Wednesday, July 8, 2026

Patent intelligence · US

US 10351589

3.alpha.-ethynyl, 3.beta.-hydroxy-5.alpha.-pregnan-20-oxime for use in the treatment of CNS disorders

granted A61KA61K31/57A61K45/06A61P
Status granted
Linked drugs 1
Pipeline programs 6
Years to expiry 13
Applicant portfolio 12
Patent details — US 10351589
Jurisdiction
US
Status
granted
Grant date
Jul 16, 2019
Expiration
Jul 11, 2039
Claims
8
CPC classes
A61K, A61K31/57, A61K45/06, A61P
View on Google Patents ↗

Quick answer

US 10351589 (3.alpha.-ethynyl, 3.beta.-hydroxy-5.alpha.-pregnan-20-oxime for use in the treatment of CNS disorders) is held by Umecrine Cognition AB. Status: granted. Granted Jul 16, 2019. Expires Jul 11, 2039 (13 years remaining) — relevant for patent-cliff and LOE planning.

Key facts

Grant date
Expiration
Claims
8
CPC classes
A61K, A61K31/57, A61K45/06, A61P, A61P1/16, A61P15/00

More from Umecrine Cognition AB

Related pharmaceutical patents in our USPTO index.

  1. US 12208167

    Coated tablets for pH-dependent release of benzgalantamine

    ALPHA COGNITION INC. · Expires Jan 23, 2045

    granted
  2. US 12157743

    Solid forms of Alpha-1062 gluconate

    ALPHA COGNITION INC. · Expires Nov 28, 2044

    granted
  3. US 11795176

    Solid forms of Alpha-1062 gluconate

    ALPHA COGNITION INC. · Expires Oct 19, 2043

    granted
  4. US 11123351

    Pharmaceutical formulation of 3-alpha-ethynyl-3-beta-hydroxyandrostan-17-one oxime

    Umecrine Cognition AB · Expires Sep 16, 2041

    granted
  5. US 10603326

    Pharmaceutical formulation of 3α-ethynyl-3β-hydroxyandrostan-17-one oxime

    Umecrine Cognition AB · Expires Mar 26, 2040

    granted
  6. US 10342804

    Steroid compound for use in the treatment of hepatic encephalopathy

    Umecrine Cognition AB · Expires Jul 4, 2039

    granted
  7. US 10278977

    Methods for treating hypersomnolence

    Umecrine Cognition AB · Expires May 2, 2039

    granted

Frequently asked questions

What is US patent 10351589?

US 10351589 (3.alpha.-ethynyl, 3.beta.-hydroxy-5.alpha.-pregnan-20-oxime for use in the treatment of CNS disorders) is held by Umecrine Cognition AB. Status: granted. Granted Jul 16, 2019. Expires Jul 11, 2039 (13 years remaining) — relevant for patent-cliff and LOE planning.

Who owns US 10351589?

Umecrine Cognition AB is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 12 pharmaceutical patents for this assignee.

When does US 10351589 expire?

Our index shows an expiration date of Jul 11, 2039 (13 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.